BACKGROUND:Peach allergy is prevalent, persistent, and potentially severe and as such is a target for immunotherapy. Our aims were to evaluate the profile of sensitization to Rosaceae allergens and the effects of sublingual peach immunotherapy on immunoglobulin (Ig) E levels to these allergens, to monitor for neosensitizations, and to check if this treatment modified other Rosaceae fruit and pollen-related sensitizations. METHODS: A double-blind placebo-controlled trial was conducted on 56 peach-allergic patients who received, sublingually, a standardized peach extract quantified in mass units of Pru p 3, orplacebo for 6 months. IgE to recombinant (r) Mal d 1, rMal d 4, rPru p 3, and natural (n) Art v 3 and skin prick test (SPT) reactivity to Platanus pollen and apple extracts evaluated before treatment (T0), after 1 month (T1) and after and 6 months (T6) were recorded. RESULTS: In total, 18.5% of patients recognized rMal d 1, 83.3%, rPru p 3, 24.1%, rMal d 4, and 25.9% nArt v 3. IgE to Pru p 3 rose from T0 to T1 in both the active group (P = .003) and the placebo group (P = .022), and remained elevated at T6 in the active group (P = .001). IgE to other purified allergens did not change significantly and no relevant neosensitizations were detected. SPT reactions to peach decreased from T0 to T6 in the active group (P < 0.05). Reactivity to peach (T1 and T6) and apple (T6) was lower in the active group than in the control group. CONCLUSIONS: The main allergen was Pru p 3. Changes in rPru p 3 IgE levels and in peach and apple extract SPT were induced by sublingual immunotherapy.
RCT Entities:
BACKGROUND:Peachallergy is prevalent, persistent, and potentially severe and as such is a target for immunotherapy. Our aims were to evaluate the profile of sensitization to Rosaceae allergens and the effects of sublingual peach immunotherapy on immunoglobulin (Ig) E levels to these allergens, to monitor for neosensitizations, and to check if this treatment modified other Rosaceae fruit and pollen-related sensitizations. METHODS: A double-blind placebo-controlled trial was conducted on 56 peach-allergicpatients who received, sublingually, a standardized peach extract quantified in mass units of Pru p 3, or placebo for 6 months. IgE to recombinant (r) Mal d 1, rMal d 4, rPru p 3, and natural (n) Art v 3 and skin prick test (SPT) reactivity to Platanus pollen and apple extracts evaluated before treatment (T0), after 1 month (T1) and after and 6 months (T6) were recorded. RESULTS: In total, 18.5% of patients recognized rMal d 1, 83.3%, rPru p 3, 24.1%, rMal d 4, and 25.9% nArt v 3. IgE to Pru p 3 rose from T0 to T1 in both the active group (P = .003) and the placebo group (P = .022), and remained elevated at T6 in the active group (P = .001). IgE to other purified allergens did not change significantly and no relevant neosensitizations were detected. SPT reactions to peach decreased from T0 to T6 in the active group (P < 0.05). Reactivity to peach (T1 and T6) and apple (T6) was lower in the active group than in the control group. CONCLUSIONS: The main allergen was Pru p 3. Changes in rPru p 3 IgE levels and in peach and apple extract SPT were induced by sublingual immunotherapy.
Authors: Laurian Zuidmeer-Jongejan; Montserrat Fernandez-Rivas; Lars K Poulsen; Angela Neubauer; Juan Asturias; Lars Blom; Joyce Boye; Carsten Bindslev-Jensen; Michael Clausen; Rosa Ferrara; Paula Garosi; Hans Huber; Bettina M Jensen; Stef Koppelman; Marek L Kowalski; Anna Lewandowska-Polak; Birgit Linhart; Bernard Maillere; Adriano Mari; Alberto Martinez; Clare En Mills; Claudio Nicoletti; Dirk-Jan Opstelten; Nikos G Papadopoulos; Antonio Portoles; Neil Rigby; Enrico Scala; Heidi J Schnoor; Sigurveig T Sigurdardottir; George Stavroulakis; Frank Stolz; Ines Swoboda; Rudolf Valenta; Rob van den Hout; Serge A Versteeg; Marianne Witten; Ronald van Ree Journal: Clin Transl Allergy Date: 2012-03-09 Impact factor: 5.871
Authors: Andrew W O'Keefe; Sarah De Schryver; Jennifer Mill; Christopher Mill; Alizee Dery; Moshe Ben-Shoshan Journal: J Asthma Allergy Date: 2014-10-24
Authors: Juan Jose Yepes-Nuñez; Yuan Zhang; Marta Roqué i Figuls; Joan Bartra Tomas; Juan Manuel Reyes; Fernando Pineda de la Losa; Ernesto Enrique Journal: Cochrane Database Syst Rev Date: 2015-11-09